<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03471234</url>
  </required_header>
  <id_info>
    <org_study_id>SCI-CO-01</org_study_id>
    <nct_id>NCT03471234</nct_id>
  </id_info>
  <brief_title>Latin America Real World Study With Inspiron Drug Eluting Stent - INSPIRON LATITUDE</brief_title>
  <acronym>LATITUDE</acronym>
  <official_title>LATIn American sTUdy to Investigate the Clinical Performance of Sirolimus-eluting Stent With Abluminal-only bioDEgradable Polymeric Coating (Inspiron TM) in the Treatment of Native Coronary Artery Lesions.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Scitech Produtos Medicos Ltda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Scitech Produtos Medicos Ltda</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, multicenter, single arm registry to monitor post-market clinical outcomes of
      patients treated with Inspiron Sirolimus-Eluting Stent with Biodegradable Polymer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, multicenter, single arm registry to assess the safety and performance of
      Inspiron Sirolimus-Eluting Stent with Biodegradable Polymer for the treatment of &quot;real world&quot;
      patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 3, 2018</start_date>
  <completion_date type="Anticipated">July 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>MACE (major cardiac events)</measure>
    <time_frame>12 months</time_frame>
    <description>Major cardiac events (death, myocardial infarction, target vessel revascularization)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute success</measure>
    <time_frame>up to 24 hours</time_frame>
    <description>Acute success measured by Angiography after stent implantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent Thrombosis</measure>
    <time_frame>24 months</time_frame>
    <description>Stent Thrombosis rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MACE</measure>
    <time_frame>24 months</time_frame>
    <description>Major cardiac events (death, myocardial infarction, target vessel revascularization)</description>
  </secondary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Coronary Artery Disease</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Angioplasty</intervention_name>
    <description>Inspiron Drug Eluting stent implantation</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with lesions in native coronary arteries measuring between 2.5 and 4.0 mm in
        diameter and 34 mm length treated only with Inspiron Sirolimus-Eluting Stent.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All individuals aged over 18 years who signed the informed consent and had lesions in
             native coronary arteries treated only with Inspiron Sirolimus-Eluting stent.

        Exclusion Criteria:

          -  Saphenous vein grafts or Mammary lesions;

          -  Individuals who have been treated within the last 6 months with another stent;

          -  Acute myocardial infarction with ST segment elevation;

          -  Chronic Total Occlusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Juliana Castro, PhD</last_name>
    <phone>+55(11) 21258099</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Erico Rossi</last_name>
    <phone>+55(11) 21258099</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Instituto Dante Pazzanese de Cardiologia</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José Costa Jr, MD</last_name>
    </contact>
    <investigator>
      <last_name>José de Ribamar Costa Jr, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto do Coração - INCOR</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henrique Ribeiro, MD</last_name>
    </contact>
    <investigator>
      <last_name>Henrique B Ribeiro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 5, 2018</study_first_submitted>
  <study_first_submitted_qc>March 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 20, 2018</study_first_posted>
  <last_update_submitted>March 16, 2020</last_update_submitted>
  <last_update_submitted_qc>March 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>coronary disease</keyword>
  <keyword>drug eluting stent</keyword>
  <keyword>Inspiron</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

